GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » EV-to-EBIT

NKGen Biotech (NKGen Biotech) EV-to-EBIT : -0.82 (As of May. 26, 2024)


View and export this data going back to 2023. Start your Free Trial

What is NKGen Biotech EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, NKGen Biotech's Enterprise Value is $57.52 Mil. NKGen Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-70.44 Mil. Therefore, NKGen Biotech's EV-to-EBIT for today is -0.82.

The historical rank and industry rank for NKGen Biotech's EV-to-EBIT or its related term are showing as below:

NKGN' s EV-to-EBIT Range Over the Past 10 Years
Min: -6.89   Med: 0   Max: 0
Current: -0.82
NKGN's EV-to-EBIT is ranked worse than
100% of 426 companies
in the Biotechnology industry
Industry Median: 10.295 vs NKGN: -0.82

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. NKGen Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $64.50 Mil. NKGen Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was $-70.44 Mil. NKGen Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -109.22%.

NKGen Biotech EV-to-EBIT Historical Data

The historical data trend for NKGen Biotech's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NKGen Biotech EV-to-EBIT Chart

NKGen Biotech Annual Data
Trend Dec21 Dec22 Dec23
EV-to-EBIT
- - -0.97

NKGen Biotech Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial - - - -0.97 -0.92

Competitive Comparison of NKGen Biotech's EV-to-EBIT

For the Biotechnology subindustry, NKGen Biotech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

NKGen Biotech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, NKGen Biotech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where NKGen Biotech's EV-to-EBIT falls into.


NKGen Biotech EV-to-EBIT Calculation

NKGen Biotech's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=57.521/-70.44
=-0.82

NKGen Biotech's current Enterprise Value is $57.52 Mil.
NKGen Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech  (NAS:NKGN) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

NKGen Biotech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-70.44/64.49521
=-109.22 %

NKGen Biotech's Enterprise Value for the quarter that ended in Mar. 2024 was $64.50 Mil.
NKGen Biotech's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-70.44 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

NKGen Biotech EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of NKGen Biotech's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

NKGen Biotech (NKGen Biotech) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » NKGen Biotech Inc (NAS:NKGN) » Definitions » EV-to-EBIT
Comparable Companies
OCUP CASI SPRO XLO NGM GBIO ASMB CCCC OCEA FIXX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
N/A
Address
19700 Fairchild Road, Suite No. 300, Irvine, CA, USA, 92612
Website
https://www.nkgenbiotech.com
NKGen Biotech Inc is a clinical-stage biotechnology company focused on the development and commercialization of innovative autologous, allogeneic and CAR-NK natural killer cell therapies utilizing our proprietary SNK (super-activated) platform.